Olin (OLN) Q2 2026 Earnings Call Transcript

Olin reported Q2 2026 sales of $1,741.9m (-0.9% YoY) but improved adjusted EBITDA to $191.3m (+$15.2m YoY), despite a $(13.3)m net loss and a $40m penalty from an unplanned Freeport, Texas VCM outage. The company reiterated Q3 adjusted EBITDA guidance of $160m–$200m (with VCM expected back to full rates late Q3) and highlighted liquidity of $1.2B and a leverage target to fall to ~4.5x by year-end. Separately, Olin is progressing its proposed $12B all-stock merger with Huntsman, with a special shareholder meeting scheduled for Aug. 25.

Analysis

The main winner is not the quarter itself but the setup into Q4: if chlor-alkali tightens as planned and the VCM repair normalizes, OLN’s earnings power can snap back faster than the market typically models for a commodity chemical name. The offset is that the equity is still highly levered to spread stability, so every incremental dollar of EBITDA matters more than the headline sales figure; that keeps the stock vulnerable if European energy costs or China operating rates fail to tighten supply. HUN benefits indirectly from the merger narrative, but the real second-order effect is that a cleaner integrated chemicals platform could rerate closer to peer industrial multiples if execution risk is credibly removed.

Near term, the biggest risk is that management’s Q3 framing becomes the ceiling rather than the floor: FIFO headwinds, outage drag, and litigation cash outflows mean the company needs multiple things to go right just to hold leverage in check. The time horizon matters: days-to-weeks reaction is likely driven by the merger vote and Q3 guidance revisions, while the 1-3 month path depends on whether working capital actually unwinds and whether exported caustic/EDC pricing stabilizes. Over 6-18 months, the thesis hinges on whether the announced synergy story is real cash flow or just balance-sheet theater.

The consensus may be underestimating Winchester’s role as a cash-flow stabilizer, which lowers dilution risk and makes the stock less fragile than a pure chemical cyclical. But the market may also be overcounting the merger synergy before close: $400mm is meaningful, yet it is too far out to justify aggressive multiple expansion today without evidence of integration discipline. Net: this is a tactical name, not a high-conviction structural long unless Q3 confirms the expected Q4 tightening in chemicals.

Key Decisions for Investors

• Tactically buy OLN only on post-earnings weakness or a pullback into the late-August merger vote window; 3-6 month thesis is Q4 EBITDA inflection from VCM normalization and tighter chlor-alkali supply. Falsify if Q3 chemicals come in below the low end of guidance or leverage stays above ~4.5x after working-capital release.
• Prefer HUN over OLN on a relative basis into the shareholder meeting: HUN has more rerating potential if the combination is approved and pre-close integration gives credibility to the synergy story. Use a modest size because the trade depends on deal optics more than near-term fundamentals.
• Avoid chasing OLN on the assumption that the Q2 pricing spike will persist; treat Q3 as a digestion quarter for the sector. If caustic/EDC export pricing rolls over again or Europe energy costs reaccelerate, trim exposure quickly.
• For longer-dated exposure, consider a small call-spread style expression in OLN only after confirmation that Q4 supply tightness is materializing; the setup is attractive only if you are paid for the leverage to a cyclical snapback. Do not use size that assumes synergy delivery before 2027.